These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10625379)

  • 1. Isis and antisense face crucial test without Novartis.
    Dove A
    Nat Biotechnol; 2000 Jan; 18(1):19. PubMed ID: 10625379
    [No Abstract]   [Full Text] [Related]  

  • 2. Sense and antisense for investors.
    Jacobs T
    Nat Biotechnol; 2002 Jun; 20(6):543. PubMed ID: 12042846
    [No Abstract]   [Full Text] [Related]  

  • 3. Genzyme and Isis strike megadeal.
    Mack GS
    Nat Biotechnol; 2008 Mar; 26(3):251-3. PubMed ID: 18327216
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysts: Isis-Lilly deal validates antisense.
    Niiler E
    Nat Biotechnol; 2001 Oct; 19(10):898-9. PubMed ID: 11581643
    [No Abstract]   [Full Text] [Related]  

  • 5. Genta strikes bumper deal with Aventis.
    Dorey E
    Nat Biotechnol; 2002 Jun; 20(6):533-4. PubMed ID: 12042842
    [No Abstract]   [Full Text] [Related]  

  • 6. Profit at a cost?
    Nat Cell Biol; 2000 Jul; 2(7):E113. PubMed ID: 10878816
    [No Abstract]   [Full Text] [Related]  

  • 7. Swooping for biotech.
    Wadman M
    Nature; 2005 Sep; 437(7058):475. PubMed ID: 16177760
    [No Abstract]   [Full Text] [Related]  

  • 8. Stuck in the middle.
    Fuyuno I
    Nature; 2006 Jul; 442(7100):237. PubMed ID: 16855561
    [No Abstract]   [Full Text] [Related]  

  • 9. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Big biotech buys iconic genetics firm.
    Baker M
    Nature; 2012 Dec; 492(7429):321. PubMed ID: 23257857
    [No Abstract]   [Full Text] [Related]  

  • 11. America's other drug problem: how the drug industry distorts medicine and politics.
    Relman AS; Angell M
    New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
    [No Abstract]   [Full Text] [Related]  

  • 12. AchemAsia 2007 announcement: China's biotechnology industry on the upswing.
    Biotechnol J; 2007 Mar; 2(3):288-90. PubMed ID: 17354215
    [No Abstract]   [Full Text] [Related]  

  • 13. In search of the élite.
    Gewin V
    Nature; 2003 Dec; 426(6967):713-7. PubMed ID: 14668879
    [No Abstract]   [Full Text] [Related]  

  • 14. Silent running: the race to the clinic.
    Nature; 2006 Aug; 442(7103):614-5. PubMed ID: 16900171
    [No Abstract]   [Full Text] [Related]  

  • 15. Medical journals, academia, and industry-sponsored clinical trials.
    Frighi V
    PLoS Med; 2005 Jul; 2(7):e218. PubMed ID: 16033312
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer pathways' target not validated by clinical results.
    Ratner M
    Nat Biotechnol; 1999 Mar; 17(3):220. PubMed ID: 10096279
    [No Abstract]   [Full Text] [Related]  

  • 17. Piercing the veil of corporate secrecy about clinical trials.
    Lemmens T
    Hastings Cent Rep; 2004; 34(5):14-8. PubMed ID: 15553393
    [No Abstract]   [Full Text] [Related]  

  • 18. Portfolio managing for scientists.
    Sable D
    Nat Biotechnol; 2010 Oct; 28(10):1131. PubMed ID: 20944607
    [No Abstract]   [Full Text] [Related]  

  • 19. There's still gold in them thar pills.
    O'Reilly B
    Fortune; 2001 Jul; 144(2):58-62, 66-8, 70. PubMed ID: 11471355
    [No Abstract]   [Full Text] [Related]  

  • 20. Sharing secrets.
    Nat Biotechnol; 2011 Apr; 29(4):291. PubMed ID: 21478827
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.